Estimating the rate of severe visual loss (wipe-out) following cataract surgery, a British Ophthalmological Surveillance Unit (BOSU) study.


Journal

Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 21 04 2022
accepted: 25 05 2023
revised: 21 03 2023
pmc-release: 01 12 2024
medline: 7 12 2023
pubmed: 17 6 2023
entrez: 16 6 2023
Statut: ppublish

Résumé

A sudden, irreversible reduction in visual acuity ('wipe-out') is a feared complication of cataract surgery. Current literature on wipe-out is limited in quantity and quality, and largely predates modern cataract surgery and imaging techniques. The objectives of our study were to estimate the incidence of wipe-out and to identify potential risk factors. We prospectively collated cases of wipe-out occurring in the UK during a 25-month study period using the British Ophthalmic Surveillance Unit reporting system. A total of 21 potential cases of wipe-out were reported, 5 of which met all inclusion and exclusion criteria. The estimated incidence of wipe-out during the study period was 0.00000298, or approximately 3 cases per million cataract operations. All cases of wipe-out occurred exclusively in patients with advanced glaucoma (mean deviation -21.0 decibels or worse in the operated eye), with an over-representation of black people (40%) in our case series. A prior diagnosis of retinal vein occlusion (60%) and elevated post-operative IOP (40%) were more common among individuals suffering from wipe-out compared to the general population, suggesting these factors may contribute to the pathogenesis of wipe-out. Our study shows that wipe-out is a rare complication, affecting approximately 3 per million undergoing cataract surgery. Patients with advanced glaucoma, black patients, and those with previous retinal vein occlusions may be at greater risk of wipe-out. We hope that the findings of our study will be used to help inform treatment decision-making and the cataract surgery consent process.

Sections du résumé

BACKGROUND BACKGROUND
A sudden, irreversible reduction in visual acuity ('wipe-out') is a feared complication of cataract surgery. Current literature on wipe-out is limited in quantity and quality, and largely predates modern cataract surgery and imaging techniques. The objectives of our study were to estimate the incidence of wipe-out and to identify potential risk factors.
METHODS METHODS
We prospectively collated cases of wipe-out occurring in the UK during a 25-month study period using the British Ophthalmic Surveillance Unit reporting system. A total of 21 potential cases of wipe-out were reported, 5 of which met all inclusion and exclusion criteria.
RESULTS RESULTS
The estimated incidence of wipe-out during the study period was 0.00000298, or approximately 3 cases per million cataract operations. All cases of wipe-out occurred exclusively in patients with advanced glaucoma (mean deviation -21.0 decibels or worse in the operated eye), with an over-representation of black people (40%) in our case series. A prior diagnosis of retinal vein occlusion (60%) and elevated post-operative IOP (40%) were more common among individuals suffering from wipe-out compared to the general population, suggesting these factors may contribute to the pathogenesis of wipe-out.
CONCLUSIONS CONCLUSIONS
Our study shows that wipe-out is a rare complication, affecting approximately 3 per million undergoing cataract surgery. Patients with advanced glaucoma, black patients, and those with previous retinal vein occlusions may be at greater risk of wipe-out. We hope that the findings of our study will be used to help inform treatment decision-making and the cataract surgery consent process.

Identifiants

pubmed: 37328508
doi: 10.1038/s41433-023-02606-9
pii: 10.1038/s41433-023-02606-9
pmc: PMC10697986
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3787-3792

Informations de copyright

© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Références

J Cataract Refract Surg. 2004 Nov;30(11):2435-7
pubmed: 15519103
Br J Ophthalmol. 2010 Jan;94(1):85-7
pubmed: 19628488
Eye (Lond). 2022 Jan;36(1):219-227
pubmed: 33686235
Klin Monbl Augenheilkd. 2006 Apr;223(4):297-302
pubmed: 16639667
Eye (Lond). 2015 Dec;29(12):1528-37
pubmed: 26493034
Eye (Lond). 2003 Jan;17(1):9-15
pubmed: 12579163
Clin Exp Ophthalmol. 2008 Apr;36(3):217-21
pubmed: 18412589
Arch Ophthalmol. 2004 Apr;122(4):564-72
pubmed: 15078675
Am J Ophthalmol. 1985 Apr 15;99(4):383-7
pubmed: 3985075
Eye (Lond). 2020 Jul;34(7):1271-1278
pubmed: 32291405
Open Heart. 2021 Feb;8(1):
pubmed: 33707223
Arch Ophthalmol. 2006 Dec;124(12):1694-700
pubmed: 17159028
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
Br J Ophthalmol. 1986 Feb;70(2):97-9
pubmed: 3947617
Am J Ophthalmol. 2005 Oct;140(4):705-6
pubmed: 16226523
Br J Ophthalmol. 1976 Feb;60(2):124-31
pubmed: 1268172
Ophthalmic Surg. 1992 Jun;23(6):388-94
pubmed: 1513534
Arch Ophthalmol. 2001 Dec;119(12):1771-9
pubmed: 11735786
Clin Exp Ophthalmol. 2018 Apr;46(3):260-265
pubmed: 28752913
Sci Rep. 2021 Jul 2;11(1):13762
pubmed: 34215769
Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):855-861
pubmed: 30569320
Arch Ophthalmol. 2007 Aug;125(8):1044-50
pubmed: 17698750
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
JAMA Ophthalmol. 2013 Oct;131(10):1275-87
pubmed: 23929382
Trans Am Ophthalmol Soc. 1977;75:539-55
pubmed: 613530

Auteurs

Conor Ramsden (C)

West of England Eye Unit, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. conor.ramsden@nhs.net.
Institute of Ophthalmology, University College London, London, UK. conor.ramsden@nhs.net.

Yusrah Shweikh (Y)

Sussex Eye Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Massachusetts Eye and Ear Infirmary, Boston, MA, USA.

Ronald Kam (R)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.

Catey Bunce (C)

Research Data & Statistics Unit (RDSU), Royal Marsden Clinical Trials Unit (RM-CTU), London, UK.

Barny Foot (B)

Royal College of Ophthalmologists, London, UK.

Ananth Viswanathan (A)

NIHR BRC at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH